Latest Announcements

BSE & NSE corporate filings with AI summaries

BSECompany Update▼ NegativeRegulatory4d ago

Centenial Surgical Suture Ltd

please find attached

Centenial Surgical Suture Ltd has observed unusual trades in its company shares, with the share price experiencing an abnormal rise, and has requested the BSE Limited to investigate the matter for possible price manipulation.

Read more →📎 1 attachment
BSEInsider Trading / SASTRegulatory4d ago

Ajanta Pharma Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust

Ajanta Pharma Ltd received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust.

Read more →📎 1 attachment
BSECompany UpdateRegulatory4d ago

Future Consumer Ltd

Certificate under Reg.74(5) of SEBI (DP) Regulations,2018

Future Consumer Ltd has submitted a certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018, stating that the company has complied with the regulations regarding the creation, invocation, or release of pledge of securities. The certificate is dated 10-03-2023 and is signed by Ashok Sethty, the Corporate Registrar.

Read more →📎 1 attachment
BSECompany UpdateRegulatory4d ago

Jay Bharat Maruti Ltd

Clarification on Volume Movement

Jay Bharat Maruti Ltd clarifies that there is no information or announcement that could be causing the significant increase in volume of its security across exchanges, stating that the volumes are market-driven and due to market conditions.

Read more →📎 1 attachment
BSECompany UpdateRegulatory4d ago

Smruthi Organics Ltd

Intimation regarding receipt of ANVISA Inspection Report

Smruthi Organics Ltd has received an inspection report from the Brazilian Health Regulatory Agency (ANVISA) for its Unit II, which has been classified as 'Complies with Good Manufacturing Practices with Corrective Action'. The report indicates conditions for certification in respect of the inspected active pharmaceutical ingredient. The company will make further disclosures upon receipt of the final GMP certificate.

Read more →📎 1 attachment